Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 2/20 | 0.35 |
| ▸ | WNT1 | P04628 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.33 |
| ▸ | TBK1 | Q9UHD2 | 5/20 | 0.33 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.32 |
| ▸ | USP7 | Q93009 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.31 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | CCR6 | P51684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20676590 | 0.90 | TBK1 (0.41) | KITWNT1GSK3BDYRK1AUSP30 | |
| SCHEMBL22358345 | 0.89 | KIT (0.37) | KITWNT1GSK3BDYRK1AUSP30 | |
| SCHEMBL20676660 | 0.87 | USP7 (0.41) | KITUSP30PIK3CDTBK1USP7 | |
| SCHEMBL20116173 | 0.81 | USP30 (0.39) | KITUSP30PIK3CDTBK1SCD5 | |
| SCHEMBL20116320 | 0.80 | USP30 (0.45) | USP30TBK1SCD5 | |
| SCHEMBL20116980 | 0.79 | USP30 (0.40) | KITUSP30PIK3CDSCD5USP7 | |
| SCHEMBL20117073 | 0.79 | USP7 (0.40) | KITWNT1GSK3BDYRK1AUSP30 | |
| SCHEMBL20116041 | 0.78 | GPR119 (0.49) | USP30TBK1USP7 | |
| SCHEMBL20116521 | 0.78 | USP7 (0.38) | KITUSP30PIK3CDTBK1USP7 | |
| SCHEMBL20116089 | 0.78 | SMO (0.42) | KITUSP30PIK3CDTBK1USP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | KIT 4491/4885WNT1 4223/4885GSK3B 741/4885 |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | KIT 4491/4885WNT1 4223/4885GSK3B 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.